Genomic Biomarkers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
收藏NIAID Data Ecosystem2026-03-13 收录
数据链接：
官方服务：
资源简介：
Supplementary figures and tables
应用场景：
创建时间：
2022-06-01
相关数据集
Store Independent Ca2+ Entry Regulates the DNA Damage Response Pathway in Breast Cancer Cells. Store Independent Ca2+ Entry Regulates the DNA Damage Response Pathway in Breast Cancer Cells
The mainstay of treatment for hormone responsive breast tumors is chemotherapy, followed by targeted endocrine therapy. The vast majority (80%) of estrogen receptor positive tumors also express wild t
NIAID Data Ecosystem140
Effect of 5a-dihydrotestosterone on breast cancer cell line MDA-MB-453
Analysis of MDA-MB-453 breast cancer cells treated with the androgen 5a-dihydrotestosterone (DHT) for 6h, 16h and 48h to define the genes that are differentially regulated in response to DHT. MDA-MB-4
NIAID Data Ecosystem90
RANK expression and Luminal BC response to CDK4/6 inhibitors
The combination of endocrine therapy (ET) with CDK4/6 inhibitors (CDK4/6i) was the most recent life-changing hallmark in metastatic Luminal breast cancer (BC). However, intrinsic and acquired resistan
NIAID Data Ecosystem70
Novel long non‐coding RNA 005620 induces epirubicin resistance of triple-negative breast cancer via regulating ITGB1 expression. Novel long non‐coding RNA 005620 induces epirubicin resistance of triple-negative breast cancer via regulating ITGB1 expression
In this study, a total of 12 differentially expressed lncRNAs were established through lncRNA sequencing analysis. Lnc005620 is one of the novel intronic lncRNAs which is highly expressed in Epi-R MDA
NIAID Data Ecosystem110
VisiumHD_6
This repository provides the Visium HD spatial transcriptomics datasets for the study titled "Spatial transcriptomics uncovers pharmacokinetic barriers and tumor-intrinsic determinants of resistance t
Zenodo2026-02-12 更新90
